142 related articles for article (PubMed ID: 37479587)
1. Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
Lee KH; Chung JH; Cho S; Lee JS; Kim H
Clin Lung Cancer; 2023 Nov; 24(7):e291-e299.e1. PubMed ID: 37479587
[TBL] [Abstract][Full Text] [Related]
2. The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas.
Kim H; Lee HJ; Hong H; Kim YJ; Kim KG; Jeon YK; Kim YT
Thorac Cancer; 2019 Jul; 10(7):1619-1627. PubMed ID: 31215177
[TBL] [Abstract][Full Text] [Related]
3. [Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas].
Dong Y; Li Y; Peng H; Jin B; Huang A; Bai H; Xiong H; Han B
Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):177-83. PubMed ID: 23601297
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
Takamochi K; Oh S; Matsunaga T; Suzuki K
J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features.
Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
Eur J Cardiothorac Surg; 2022 Mar; 61(4):769-777. PubMed ID: 34791156
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas.
Liu WS; Zhao LJ; Pang QS; Yuan ZY; Li B; Wang P
Med Oncol; 2014 Jan; 31(1):771. PubMed ID: 24248816
[TBL] [Abstract][Full Text] [Related]
10. Prognostic influence of epidermal growth factor receptor mutation and radiological ground glass appearance in patients with early-stage lung adenocarcinoma.
Aokage K; Miyoshi T; Wakabayashi M; Ikeno T; Suzuki J; Tane K; Samejima J; Tsuboi M
Lung Cancer; 2021 Oct; 160():8-16. PubMed ID: 34365179
[TBL] [Abstract][Full Text] [Related]
11. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component.
Xu Y; Zheng M; Wang N; Wang R
Med Sci Monit; 2019 Nov; 25():8492-8498. PubMed ID: 31710020
[TBL] [Abstract][Full Text] [Related]
13. The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010.
Ito H; Date H; Shintani Y; Miyaoka E; Nakanishi R; Kadokura M; Endo S; Chida M; Yoshino I; Suzuki H;
BMC Cancer; 2022 Aug; 22(1):875. PubMed ID: 35948946
[TBL] [Abstract][Full Text] [Related]
14. Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity.
Li M; Xi J; Zhang H; Jin X; Zhang J; Feng M; Zhan C; Wang Q
Ann Thorac Cardiovasc Surg; 2022 Oct; 28(5):320-328. PubMed ID: 35644565
[TBL] [Abstract][Full Text] [Related]
15. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
16. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
17. Effect of Tegafur-Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study.
Aoki M; Miyata R; Kamimura G; Harada Takeda A; Suetsugu T; Mizuno K; Ueda K
Ann Thorac Cardiovasc Surg; 2024 Jan; 30(1):. PubMed ID: 38105006
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
[TBL] [Abstract][Full Text] [Related]
19. Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.
Hong SJ; Kim TJ; Choi YW; Park JS; Chung JH; Lee KW
Eur Radiol; 2016 Oct; 26(10):3660-8. PubMed ID: 26787602
[TBL] [Abstract][Full Text] [Related]
20. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]